Search

… Sunday, September 30, 2007 This summer we witnessed young scientists at various crossroads in their careers. Our inaugural class of PhD students completed their first year of study and took the important step of choosing their thesis laboratories. We welcomed our second class of PhD students, who, at

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.

… Friday, April 1, 2011 Summary Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers. A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, “Where should I be treated?” Patients diagnosed with

Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

… Thursday, May 15, 2025 A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of life had reduced risk of developing a peanut allergy compared with children who avoided peanuts. Now, researchers at Memorial Sloan Kettering Cancer Center

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.

… Thursday, June 13, 2024 On June 13, 2024, a targeted drug called  repotrectinib (Augtyro TM ) received accelerated approval from the US Food and Drug Administration (FDA) for treating cancers caused by gene changes called  NTRK fusions. The clinical trial that resulted in the approval was led globally

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

… Thursday, May 19, 2011 A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center. The findings, which

Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.

… Wednesday, October 14, 2020 Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Further treatments may provide symptom relief but are rarely definitive for disease management in this cohort. Recognizing the significant unmet needs

Learn more about world-class cancer care on Long Island at MSK Nassau.

… Tuesday, March 26, 2019 Summary Memorial Sloan Kettering has opened MSK Nassau , expanding its cancer care in Nassau County. The Uniondale facility includes a number of features designed to make treatment easier and more convenient. Memorial Sloan Kettering has been caring for people on Long Island for

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.

… Friday, February 2, 2018 Summary MSK investigators are reporting on a new approach for treating melanoma in the arm or leg. The therapy combines the immunotherapy drug ipilimumab with chemotherapy for only the affected limb. For some people with cancer, drugs that help the immune system recognize and

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy

… Friday, August 10, 2018 Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy. In the phase II study, which included 32 patients, 84 percent

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

… Thursday, May 1, 2014 Summary Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve. Computational biologist Joao Xavier has spent most of his career researching how bacterial cells interact with one another and produce complex group behaviors